ABEO - Abeona Therapeutics Inc.
| Previous Close | 7.59 |
| Open | 7.31 |
| Bid | 7.48 x 800 |
| Ask | 7.48 x 800 |
| Day's Range | 7.25 - 7.66 |
| 52 Week Range | 6.94 - 22.00 |
| Volume | 264,193 |
| Avg. Volume | 621,527 |
| Market Cap | 358.145M |
| Beta (3Y Monthly) | 2.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.33 |
- GlobeNewswire•7 days ago
Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 13, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene.
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
Q3 2018 Abeona Therapeutics Inc Earnings Call
- Zacks•11 days ago
Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Abeona Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 34 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•11 days ago
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage.
- Simply Wall St.•13 days ago
What Kind Of Share Price Volatility Should You Expect For Abeona Therapeutics Inc (NASDAQ:ABEO)?
If you own shares in Abeona Therapeutics Inc (NASDAQ:ABEO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•15 days ago
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20.
- PR Newswire•15 days ago
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
ROCKVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1 (CLN1 Disease), and Juvenile Batten Disease, also known as neuronal ceroid lipofuscinosis type 3 (CLN3 Disease).
- GlobeNewswire•last month
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
NEW YORK and CLEVELAND, Oct. 18, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Cincinnati Bell, Hooker Furniture, AgroFresh Solutions, Forward Industries, Abeona Therapeutics, and Sientra — Discovering Underlying Factors of Influence
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Market Realist•2 months agoHow Abeona Therapeutics Stock Is Doing
Yesterday, Abeona Therapeutics (ABEO) stock closed at $13, ~75% below its 52-week high of $22.75 on October 11, 2017. This month, Abeona stock has fallen 15% from $15.40 on August 31. Abeona’s 52-week low is $10.50, which it reached on February 15.
- GlobeNewswire•2 months ago
Abeona Announces Participation at Upcoming Conferences
NEW YORK and CLEVELAND, Sept. 28, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
- Simply Wall St.•2 months ago
When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Become Profitable?
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. With the latest financial yearRead More...
Market Realist•2 months agoAnalysts Still Bullish about BioLife Solutions
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
- GlobeNewswire•2 months ago
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
Clinical trial for ABO-101 marks the 2nd MPS III program in Europe Company plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom NEW YORK and ...
- GlobeNewswire•3 months ago
Abeona Announces Participation at Upcoming Conferences
Citi's 13th Annual Biotech Conference- September 5-6 th in Boston, MA Jefferies Gene Therapy Summit- September 27 th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018-- Abeona Therapeutics Inc., a ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ABEO earnings conference call or presentation 10-Aug-18 2:00pm GMT
Q2 2018 Abeona Therapeutics Inc Earnings Call
- Zacks•3 months ago
Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Abeona Therapeutics: 2Q Earnings Snapshot
The Dallas-based company said it had a loss of 25 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- Zacks•4 months ago
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•5 months ago
Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities
Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
- Business Wire•5 months ago
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
